Morning Movers: Darden rises following first quarter results

Check out this morning’s top movers from around Wall Street, compiled by The Fly. 

HIGHER –

• Edgewise Therapeutics (EWTX) up 29% after announcing top-line data of EDG-7500 from the Phase 1 trial in healthy subjects and the single-dose arm of the Phase 2 CIRRUS-HCM trial in patients with obstructive HCM
• Galmed (GLMD) up 23% after reporting that based on the recently published results from the Open-Label part of its Phase 3 NASH study, new scientific publications on the role of SCD1 as a critical metabolic signaling hub and an extended cash runway, it plans to broaden its drug development activities
• Mobileye (MBLY) up 7% after Intel (INTC) said it currently does not have any plans to divest a majority interest in the company
• Builders FirstSource (BLDR) up 4% after announcing that as part of a planned succession, its board of directors has named Peter Jackson, CFO, as the company’s next president and CEO, succeeding Dave Rush
• EVgo (EVGO) up 3% after appointing Paul Dobson as CFO

UP AFTER EARNINGS –

• Darden (DRI) up 7%
• FactSet (FDS) up 3%

DOWN AFTER EARNINGS –

• Endava (DAVA) down 4%
• Steelcase (SCS) down 9%

LOWER –

• Vivos Therapeutics (VVOS) down 23% after $4.3M registered direct offering at $3.15 per share
• Vanda Pharmaeuticals (VNDA) down 12% after the FDA declined to approve Vanda’s new drug application of tradipitant
• Progyny (PGNY) down 24% after a client elected to exercise a 90-day option to terminate its services agreement with the company